White coat hypertension - Open Access .click

Results 191 to 200 of about 33,532 (321)

Complications of White-coat Hypertension Compared to a Normotensive and Hypertensive Population.

Heart Views, 2021
Taher ZA +5 more
europepmc +1 more source

Cardiovascular Alterations and Management of Patients With White Coat Hypertension: A Meta-Analysis. [PDF]

Front Pharmacol, 2020
Xiang H +6 more
europepmc +1 more source

Which Patients With Dysfunctional Voiding Respond Well to Sacral Neuromodulation? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims Dysfunctional voiding (DV) is characterised by fluctuating or intermittent urinary flow during voiding in neurologically normal individuals. Given the different definitions used and heterogeneous pathophysiologies, outcomes following sacral neuromodulation/sacral nerve stimulation (SNM/SNS) are variably reported.
Jalesh N. Panicker +8 more
wiley +1 more source

Independent sector treatment centres: learning from a Scottish case study [PDF]

, 2009
Kirkwood, Graham, Pollock, Allyson M.
core +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

Polymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley +1 more source

HADS-A in White Coat Hypertension: Limitations and Future Directions. [PDF]

Anatol J Cardiol
Li Y, Sun P, Xu Z, Zhao X.
europepmc +1 more source

American Versus European Hypertension Guidelines: The Case of White Coat Hypertension. [PDF]